Eriksson, B. I.; Dahl, O. E.; Ahnfelt, L.; Kälebo, P.; Stangier, J.; Nehmiz, G.; Hermansson, K.; Kohlbrenner, V. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. Journal of thrombosis and haemostasis : JTH (Wiley). 2004-08-26, 2 (9): 1573–1580. ISSN 1538-7933. PMID 15333033. doi:10.1111/j.1538-7836.2004.00890.x.
Eriksson, BI; Dahl, OE; Büller, HR; Hettiarachchi, R; Rosencher, N; Bravo, ML; Ahnfelt, L; Piovella, F; Stangier, J; Kälebo, P; Reilly, P, A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial., Journal of thrombosis and haemostasis : JTH, 2005, 3 (1), ISSN 1538-7933, PMID 15634273, doi:10.1111/j.1538-7836.2004.01100.x
Eriksson, Bengt I; Dahl, Ola E; Rosencher, Nadia; Kurth, Andreas A; van Dijk, C Niek; Frostick, Simon P; Prins, Martin H; Hettiarachchi, Rohan; Hantel, Stefan; Schnee, Janet; Büller, Harry R. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (London, England) (Elsevier BV). 2007-09-15, 370 (9591): 949–956. ISSN 0140-6736. PMID 17869635. doi:10.1016/s0140-6736(07)61445-7.
Stangier, J; Eriksson, BI; Dahl, OE; Ahnfelt, L; Nehmiz, G; Stähle, H; Rathgen, K; Svärd, R, Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement., Journal of clinical pharmacology, 2005, 45 (5), ISSN 0091-2700, PMID 15831779, doi:10.1177/0091270005274550
Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. March 2011, 123 (10): 1144–50. PMID 21321155. doi:10.1161/CIR.0b013e31820f14c0.
Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W (April 2002). "Structure-based design of novel potent nonpeptide thrombin inhibitors". J Med Chem 45 (9): 1757–66. doi:10.1021/jm0109513. PMID 11960487. Lay summary.
Turpie AG (January 2008). "New oral anticoagulants in atrial fibrillation". Eur Heart J 29 (2): 155–65. doi:10.1093/eurheartj/ehm575. PMID 18096568.
Connolly S, Ezekowitz MD, Yusuf S, et al. (2009). "Dabigatran versus warfarin in patients with atrial fibrillation". N Engl J Med 361 (12): 1139–51. doi:10.1056/NEJMoa0905561. PMID 19717844.
Merli G, Spyropoulos AC, Caprini JA (August 2009). "Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations". Ann Surg 250 (2): 219–28. PMID 19638915.
Eriksson, B. I.; Dahl, O. E.; Ahnfelt, L.; Kälebo, P.; Stangier, J.; Nehmiz, G.; Hermansson, K.; Kohlbrenner, V. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. Journal of thrombosis and haemostasis : JTH (Wiley). 2004-08-26, 2 (9): 1573–1580. ISSN 1538-7933. PMID 15333033. doi:10.1111/j.1538-7836.2004.00890.x.
Eriksson, BI; Dahl, OE; Büller, HR; Hettiarachchi, R; Rosencher, N; Bravo, ML; Ahnfelt, L; Piovella, F; Stangier, J; Kälebo, P; Reilly, P, A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial., Journal of thrombosis and haemostasis : JTH, 2005, 3 (1), ISSN 1538-7933, PMID 15634273, doi:10.1111/j.1538-7836.2004.01100.x
Eriksson, Bengt I; Dahl, Ola E; Rosencher, Nadia; Kurth, Andreas A; van Dijk, C Niek; Frostick, Simon P; Prins, Martin H; Hettiarachchi, Rohan; Hantel, Stefan; Schnee, Janet; Büller, Harry R. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (London, England) (Elsevier BV). 2007-09-15, 370 (9591): 949–956. ISSN 0140-6736. PMID 17869635. doi:10.1016/s0140-6736(07)61445-7.
Stangier, J; Eriksson, BI; Dahl, OE; Ahnfelt, L; Nehmiz, G; Stähle, H; Rathgen, K; Svärd, R, Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement., Journal of clinical pharmacology, 2005, 45 (5), ISSN 0091-2700, PMID 15831779, doi:10.1177/0091270005274550
Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. March 2011, 123 (10): 1144–50. PMID 21321155. doi:10.1161/CIR.0b013e31820f14c0.
Eriksson, B. I.; Dahl, O. E.; Ahnfelt, L.; Kälebo, P.; Stangier, J.; Nehmiz, G.; Hermansson, K.; Kohlbrenner, V. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. Journal of thrombosis and haemostasis : JTH (Wiley). 2004-08-26, 2 (9): 1573–1580. ISSN 1538-7933. PMID 15333033. doi:10.1111/j.1538-7836.2004.00890.x.
Eriksson, BI; Dahl, OE; Büller, HR; Hettiarachchi, R; Rosencher, N; Bravo, ML; Ahnfelt, L; Piovella, F; Stangier, J; Kälebo, P; Reilly, P, A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial., Journal of thrombosis and haemostasis : JTH, 2005, 3 (1), ISSN 1538-7933, PMID 15634273, doi:10.1111/j.1538-7836.2004.01100.x
Eriksson, Bengt I; Dahl, Ola E; Rosencher, Nadia; Kurth, Andreas A; van Dijk, C Niek; Frostick, Simon P; Prins, Martin H; Hettiarachchi, Rohan; Hantel, Stefan; Schnee, Janet; Büller, Harry R. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (London, England) (Elsevier BV). 2007-09-15, 370 (9591): 949–956. ISSN 0140-6736. PMID 17869635. doi:10.1016/s0140-6736(07)61445-7.
Stangier, J; Eriksson, BI; Dahl, OE; Ahnfelt, L; Nehmiz, G; Stähle, H; Rathgen, K; Svärd, R, Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement., Journal of clinical pharmacology, 2005, 45 (5), ISSN 0091-2700, PMID 15831779, doi:10.1177/0091270005274550